Candida infections are quite prevalent and constitute a significant etiological factor in the development of severe medical diseases attributed to fungal pathogens. This is particularly observed in individuals with compromised immune systems or those who are hospitalized. Candida albicans is well recognized as one of the most significant and widespread strain of candida, contributing to several nosocomial infections and posing a significant risk to individuals' lives. The emergence of drug resistance in this particular disease has rendered numerous antifungal treatments ineffective, hence necessitating the imperative creation of highly efficacious fungicidal medications. The discipline of heterocyclic chemistry, specifically focusing on molecules featuring a 1,2,4-triazole scaffold, has emerged as a captivating area of research in recent times. The nucleus under consideration exhibits a wide range of biological activities, as documented in several scientific publications over the past thirty years. These studies have focused on the application of the 1,2,4-triazole nucleus in the creation of fungicidal drugs targeting Candida albicans. This study presents a comprehensive overview of numerous studies that have investigated the development of 1,2,4-triazole derivatives for their efficacy against Candida albicans. The elucidation of structure-activity relationships (SAR) serves as a valuable tool for contemporary medicinal chemists in the development and synthesis of novel target compounds containing the 1,2,4-triazole nucleus. This approach facilitates the development of effective medical medicines that exhibit desirable attributes such as selectivity, safety, and efficacy.